Ziyi Xu

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 8

Top Topics

Tyrosine Kinase

Small Cell Lung Cancer

Peritoneal Dialysis

Top Venues

Thoracic cancer

Cancer management and research

Evidence-based complementary and alternative medicine : eCAM

This page only lists publications with an associated author ORCID identifier.

Publications

Yan Li, Ziyi Xu, Shou-Zheng Wang, Yi-Xiang Zhu, Di Ma, Yuxin Mu, Jian-Ming Ying, Jun-Ling Li, Pu-Yuan Xing
Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA. Thoracic cancer 13 (15) (2022)
Ziyi Xu, Fei Teng, Xuezhi Hao, Junling Li, Puyuan Xing
Bevacizumab Combined with Continuation of EGFR -TKIs in NSCLC Beyond Gradual Progression. Cancer management and research 14 (2022)
Ziyi Xu, Xuezhi Hao, Qi Wang, Jing Wang, Ke Yang, Shouzheng Wang, Fei Teng, Junling Li, Puyuan Xing
Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor ( EGFR -TKI) in EGFR -Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients. Cancer management and research 14 (2022)
Ziyi Xu, Xuezhi Hao, Lin Lin, Jun-Ling Li, Puyuan Xing
Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation. Thoracic cancer 12 (16) (2021)
Teng Li, Shouzheng Wang, Jianming Ying, Yan Wang, Xing-Sheng Hu, Xuezhi Hao, Ziyi Xu, Puyuan Xing, Jun-Ling Li
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Thoracic cancer 12 (21) (2021)
Puyuan Xing, Mengzhao Wang, Jun Zhao, Wei Zhong, Yujia Chi, Ziyi Xu, Jun-Ling Li
Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. Thoracic cancer 12 (20) (2021)
Ziyi Xu, Teng Li, Xingsheng Hu, Xuezhi Hao, Puyuan Xing, Jun-Ling Li
Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC). Thoracic cancer 12 (17) (2021)
Tongji Xie, Zihua Zou, Chengcheng Liu, Yi-Xiang Zhu, Ziyi Xu, Le Wang, Jun-Ling Li, Pu-Yuan Xing
Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis. Evidence-based complementary and alternative medicine : eCAM 2021 (2021)